Valuation: Jazz Pharmaceuticals plc

Market Cap 16.01B 14.08B 13.09B 12.02B 22.56B 1,546B 22.94B 155B 60.72B 758B 60.1B 58.8B 2,622B P/E 2026 *
18x
P/E 2027 * 16.3x
Enterprise Value 17.71B 15.58B 14.48B 13.3B 24.95B 1,710B 25.37B 172B 67.16B 838B 66.47B 65.04B 2,901B EV / Sales 2026 *
3.92x
EV / Sales 2027 * 3.31x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week+4.83%
Current month+5.35%
1 month+10.26%
3 months+26.96%
6 months+50.48%
Current year+49.34%
1 week 242.11
Extreme 242.11
256.75
1 month 224.95
Extreme 224.95
256.75
Current year 156.95
Extreme 156.95
256.75
1 year 105
Extreme 105
256.75
3 years 95.49
Extreme 95.49
256.75
5 years 95.49
Extreme 95.49
256.75
10 years 86.88
Extreme 86.88
256.75
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 62 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2003-02-28
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Founder

-6,000 0.0096%
6/30/26 Tax

General Counsel

-2,678 0.0043%
6/30/26 Tax

Chief Financial Officer

-3,343 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%+4.83%+116.35%+93.93% 16.01B
+0.86%+2.30%+49.71%+158.86% 1,057B
+1.59%+5.37%+55.77%+54.77% 624B
+0.95%+1.95%+36.11%+80.44% 454B
+1.60%+7.09%+35.90%+29.32% 341B
-0.60%+2.95%+36.28%+39.04% 297B
-0.14%+0.33%+18.70%+17.64% 262B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+1.20%+21.61%+60.14% 201B
-1.18%-5.13%+13.87%+60.35% 162B
Average +0.15%+1.22%+35.67%+55.23% 363B
Weighted average by Cap. +0.12%+1.58%+36.97%+76.91%

Financials

2026 *2027 *
Net sales 4.51B 3.97B 3.69B 3.39B 6.36B 436B 6.46B 43.82B 17.11B 214B 16.94B 16.57B 739B 4.84B 4.26B 3.96B 3.63B 6.82B 467B 6.94B 47.02B 18.36B 229B 18.17B 17.78B 793B
Net income 1.02B 900M 836M 768M 1.44B 98.77B 1.47B 9.93B 3.88B 48.41B 3.84B 3.76B 168B 1.07B 939M 873M 802M 1.5B 103B 1.53B 10.37B 4.05B 50.53B 4.01B 3.92B 175B
Net Debt 1.7B 1.49B 1.39B 1.28B 2.39B 164B 2.43B 16.49B 6.44B 80.38B 6.37B 6.24B 278B 15.43M 13.57M 12.62M 11.58M 21.74M 1.49B 22.11M 150M 58.51M 730M 57.92M 56.67M 2.53B
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-07-24 US$253.87 -0.39% 538,211
26-07-23 US$254.87 +1.78% 527,986
26-07-22 US$250.41 -1.50% 521,018
26-07-21 US$254.22 +4.42% 810,118
26-07-20 US$243.47 -1.64% 675,844
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
253.87USD
Average target price
266.90USD
Spread / Average Target
+5.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JAZZ Stock